Demyelinating disorders

Demyelinating disorders

A group of diseases characterized by the breakdown of myelin, the fatty sheath surrounding and insulating nerve fibers. This breakdown interferes with nerve function, and can result in paralysis. Multiple sclerosis is a demyelinating disorder.
Mentioned in: Transverse Myelitis
References in periodicals archive ?
1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders.
ACP also manages the MS Discovery Forum, an online resource that helps researchers, people with MS and other MS stakeholders across the globe stay abreast of key findings by delivering high-quality news and information about research activities in multiple sclerosis and other demyelinating disorders.
Normal nerve function is lost in demyelinating disorders, such as MS and the rare, fatal, childhood disease, Krabbe's disease.
Germany) bring together 21 chapters by neurologists and other medical specialists from North America, Europe, and Israel who discuss advances in the diagnosis and treatment of multiple sclerosis and demyelinating disorders, including clinically isolated syndromes, pediatric MS, transverse myelitis, acute disseminated encephalomyelitis, and neuromyelitis optica.
With Promise: 2010 funding, the Society established the first-of-its-kind network of six Pediatric MS Centers of Excellence to provide comprehensive evaluation and care to children with MS and related central nervous system demyelinating disorders.
It might be particularly difficult to differentiate ADEM from CIS since they are practically both isolated monophasic demyelinating disorders.
Cases of CNS demyelinating disorders have been reported, although the causal relationship to Enbrel remains unclear.
They are also "essential to help place into context reports of the onset or exacerbation of demyelinating disorders in patients taking anti-TNF[alpha] therapies for conditions such as rheumatoid arthritis, psoriasis, and IBD.
MOG may be a primary target antigen in immune-mediated demyelinating disorders such as multiple sclerosis.
It has already been clearly established that vaccines can lead to demyelinating disorders (4).
This short-circuiting phenomenon leads to a broad range of symptoms in multiple sclerosis, the most common of the demyelinating disorders.
The benefits and risks of anti-TNF treatment should be carefully considered before initiation of SIMPONI therapy in patients with pre-existing or recent onset of demyelinating disorders.